A case report of de novo hepatocellular carcinoma after living donor liver transplantation

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Yu, Songfeng ^a,b   Guo, Hua ^a,b   Zhuang, Li ^a,b   Yu, Jun ^a,b   Yan, Sheng ^a,b   Zhang, Min ^a,b   Wang, Weilin ^a,b   Zheng, Shusen ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

Author keywords

De novo hepatocellular carcinoma; Hepatitis B recurrence; Liver transplantation; Living donor liver transplantation; YMDD mutation

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; ANTIFUNGAL AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SURFACTANT PROTEIN A; TACROLIMUS; THYROID TRANSCRIPTION FACTOR 1;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; ASPERGILLOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; FEVER; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; LUNG METASTASIS; LUNG MYCOSIS; LYMPHOCYTIC INFILTRATION; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RESPIRATORY FAILURE; STEATOSIS; TREATMENT DURATION;

ADULT; CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84881057890     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-176     Document Type: Article

References (24)

1. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009, 15(Suppl 2):S90-S94.
2. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008, 8:1982-1989. 10.1111/j.1600-6143.2008.02351.x, 18727702.
3. Torbenson M, Grover D, Boitnott J, Klein A, Molmenti E. De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B. Transplant Proc 2005, 37:2205-2206. 10.1016/j.transproceed.2005.03.093, 15964379.
4. Saxena R, Ye MQ, Emre S, Klion F, Nalesnik MA, Thung SN. De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl Surg 1999, 5:81-82. 10.1002/lt.500050111, 9873096.
5. Levitsky J, Faust TW, Cohen SM, Te HS. Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl 2002, 8:572. 10.1053/jlts.2002.33275, 12037793.
6. Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI. De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci 2006, 51:1780-1782. 10.1007/s10620-006-9333-8, 16967310.
7. Flemming P, Tillmann HL, Barg-Hock H, Kleeberger W, Manns MP, Klempnauer J, Kreipe HH. Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation 2003, 76:871-873. 10.1097/01.TP.0000082819.85398.59, 14501871.
8. Kita Y, Klintmalm G, Kobayashi S, Yanaga K. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig Dis Sci 2007, 52:3392-3393. 10.1007/s10620-006-9574-6, 17404871.
9. Sotiropoulos GC, Frilling A, Molmenti EP, Brokalaki EI, Beckebaum S, Omar OS, Broelsch CE, Malagó M. De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified?. Transplantation 2006, 82:1112.
10. Vernadakis S, Poetsch M, Weber F, Treckmann J, Mathe Z, Baba HA, Paul A, Kaiser GM. Donor origin de novo HCC in a noncirrhotic liver allograft 3 years after liver transplantation. Transpl Int 2010, 23:341-343. 10.1111/j.1432-2277.2009.00942.x, 19737373.
11. Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, Nagata S, Sugimachi K, Gion T, Shirabe K, Maehara Y. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl 2009, 15:1412-1416. 10.1002/lt.21894, 19877253.
12. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006, 12:253-258. 10.1002/lt.20701, 16447195.
13. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001, 7:S109-S118. 10.1053/jlts.2001.28645, 11689783.
14. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005, 352:1371-1373. 10.1056/NEJMe058018, 15800234.
15. Penn I. Posttransplant malignancies. Transplant Proc 1999, 31:1260-1262. 10.1016/S0041-1345(98)01987-3, 10083562.
16. Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Yoon SY, Park CS, Park YH, Lee HJ, Lee SG. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transplant Proc 2012, 44:802-805. 10.1016/j.transproceed.2012.01.027, 22483500.
17. Shimizu T, Hayashi M, Inoue Y, Komeda K, Asakuma M, Hirokawa F, Miyamoto Y, Tanigawa N, Uchiyama K. A case of gastric cancer after living donor liver transplantation. Ann Transplant 2012, 17:122-126.
18. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002, 35:S79-S85.
19. Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008, 134:1890-1899. quiz 2155, 10.1053/j.gastro.2008.02.064, 18424269.
20. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006, 26:162-170. 10.1055/s-2006-939758, 16673294.
21. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005, 12:364-372. 10.1111/j.1365-2893.2005.00620.x, 15985006.
22. Sheng YJ, Liu JY, Tong SW, Hu HD, Zhang DZ, Hu P, Ren H. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 2011, 8:393. 10.1186/1743-422X-8-393, 3173393, 21824397.
23. Mas VR, Maluf DG, Dumur CI, Archer KJ, Yanek K, Jackson-Cook C, Fisher RA. Molecular techniques for identifying HCC origin and biology after orthotopic liver transplantation. Diagn Mol Pathol 2006, 15:90-94. 10.1097/00019606-200606000-00005, 16778589.
24. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2010, 40:145-152. 10.1111/j.1872-034X.2009.00582.x, 19788684.